Purpose This open-label, prospective, multicenter single-arm phase II study combined
bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of …

PURPOSE: To determine the safety of the addition of bevacizumab to standard radiation
therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM) …

PURPOSE: To assess interim safety and tolerability of a 10-patient, Phase II pilot study using
bevacizumab (BV) in combination with temozolomide (TMZ) and regional radiation therapy …

Purpose: To determine if the addition of bevacizumab to radiation therapy and
temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly …

In previous trials, bevacizumab failed to prolong the overall survival time in newly diagnosed
glioblastoma and at the first recurrence. Randomized clinical trials at the second or further …

Background Standard therapy for newly diagnosed glioblastoma is radiotherapy plus
temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab …

Background Concurrent treatment with temozolomide and radiotherapy followed by
maintenance temozolomide is the standard of care for patients with newly diagnosed …

Purpose: To evaluate the efficacy of adding bevacizumab, a vascular endothelial growth
factor (VEGF) inhibitor, and everolimus, a mammalian target of rapamycin (mTOR inhibitor) …

Despite treatment with the current standard-of-care therapies, patients with newly diagnosed
glioblastoma multiforme (GBM) exhibit dismal prognoses. Bevacizumab has demonstrated …

Background Prognosis of unresectable glioblastoma (GB) remains poor, despite
temozolomide (TMZ)-based chemoradiation. Activity of bevacizumab (BEV) and irinotecan …